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Artificial Intelligence based Models 
for Screening of Hematologic 
Malignancies using Cell Population 
Data
Shabbir Syed-Abdul1, Rianda-Putra Firdani1,8, Hee-Jung Chung2,7*, Mohy Uddin3,8, Mina Hur2, 
Jae Hyeon Park4,7, Hyung Woo Kim5,7, Anton Gradišek6 & Erik Dovgan6
Cell Population Data (CPD) provides various blood cell parameters that can be used for differential 
diagnosis. Data analytics using Machine Learning (ML) have been playing a pivotal role in 
revolutionizing medical diagnostics. This research presents a novel approach of using ML algorithms 
for screening hematologic malignancies using CPD. The data collection was done at Konkuk University 
Medical Center, Seoul. A total of (882 cases: 457 hematologic malignancy and 425 hematologic non-
malignancy) were used for analysis. In our study, seven machine learning models, i.e., SGD, SVM, RF, 
DT, Linear model, Logistic regression, and ANN, were used. In order to measure the performance of our 
ML models, stratified 10-fold cross validation was performed, and metrics, such as accuracy, precision, 
recall, and AUC were used. We observed outstanding performance by the ANN model as compared 
to other ML models. The diagnostic ability of ANN achieved the highest accuracy, precision, recall, 
and AUC ± Standard Deviation as follows: 82.8%, 82.8%, 84.9%, and 93.5% ± 2.6 respectively. ANN 
algorithm based on CPD appeared to be an efficient aid for clinical laboratory screening of hematologic 
malignancies. Our results encourage further work of applying ML to wider field of clinical practice.
The global burden of blood cancers is rising and it has affected the lives of millions of people with all ages globally. 
Hematological malignancies have a major contribution in disease burden almost in every country. The status 
report produced by the International Agency for Research on Cancer (IARC) estimated 18.1 million new cancer 
cases and 9.6 million cancer deaths in 2018; 1 out of 5 men and 1 out of 6 women get cancer in their life, and 1 out 
of 8 men and 1 out of 11 women die due to cancer; and the estimated 5 year prevalence of cancer is 43.8 million1. 
According to the detailed systematic analyses from Global Burden of Disease Cancer Collaboration, the current 
cancer trends pose a threat to human development, and if these trends continue then the cancer incidence and 
prevalence are expected to increase in the future due to population growth, ageing and epidemiological transi-
tions2,3. These facts highlight the importance and urgency of implementing efficient prevention and early detec-
tion policies for cancer along with the strategic investments and effective programs for cancer control in order 
to provide universal access to cancer care and achieve the global health action plans2,4. Clinical and biological 
classifications have been developed by the World Health Organization (WHO) to recognize, categorize and treat 
the hematological malignancies5. Various clinical methods and techniques, such as biopsies, blood tests, immu-
nology tests, flow cytometry, radiology exams, as well as genetics technologies, such as chromosome analysis and 
DNA sequencing exist for the diagnosis of hematological malignancies6,7. Complete Blood Count (CBC) is one 
of the basic and fundamental tests to evaluate a variety of health disorders including hematological malignancies. 
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With technological innovations, the Next-Generation Hematological Analyzers (HA) are instrumental in cellular 
and morphological analysis8. Though these analyzers are most commonly used for cell counts and differential leu-
kocyte analysis, but their maximum potentials still need to be utilized8. They can provide additional parameters 
to support the screening and diagnosis of different diseases, e.g. they can expand the potential information from 
CBC8,9. The Cell Population Data (CPD) generated from these analyzers provides various blood cell parameters 
and have proved its usefulness in the screening of hematological and non-hematological diseases10. The literature 
has provided successful examples of utilizing clinical information using CPD parameters for diagnosis and man-
agement of infectious diseases, such as Sepsis9,10.
With the advent of time, latest Information and Communication Technologies (ICTs) are paving the way 
for new discoveries of screening, diagnosing and predicting diseases; and Artificial Intelligence (AI) is one of 
the most influential names in that technological list. AI is the field of computer science that simulates human 
intelligence by creating intelligent machines. It has great potentials to identify the relevant clinical information 
that is hidden in large scale or big healthcare data. AI and its branches, such as Machine Learning (ML) have 
made remarkable achievements in healthcare industry in the past decades and have been playing a pivotal role in 
revolutionizing the medical diagnostics and practices through intelligent applications and tools. Some important 
uses of ML applications in clinical practice include: provision of up-to-date information for reducing diagnostic 
and therapeutic errors, real time inferences, health risk alerts, and health outcome predictions11,12. Though there 
is substantial literature of AI and ML in healthcare research, most of the research focuses in the fields of Cancer, 
Neurology and Cardiology11,13–21. In addition, the literature lacks successful applications of ML that deal with 
complex medical diagnostic fields like Hematology22. Blood tests are the most common measure to diagnose 
the hematological diseases in the laboratories and clinicians need the hematological parameters to analyze the 
numerical patterns, deviations and relations; and that’s where ML algorithms can come into action by performing 
intelligent handling, detection and utilization of these parameters, and developing models to predict the future 
diagnosis and outcomes22.
This research presents a novel approach of using ML algorithms for screening patients for hematologic malig-
nancies using CPD. The term screening refers to the medical process of determining the likelihood of disease 
in healthy population; and based on subsequent diagnostic tests or procedures, it can lead to the intervention / 
treatment of the diagnosed disease. Therefore, our proposed approach is not and cannot be used for diagnosing 
or treating the malignancies, rather it just provides a simple technological support for screening the patients using 
their numerical data. In order to measure the performance of ML models, stratified 10-fold cross validation was 
performed, and metrics like accuracy, precision, recall, Area Under the Curve (AUC), and Receiver Operating 
Characteristic (ROC) were used.
Methods
This study was performed in Konkuk University Medical Center (KUMC), which is 700-bed sized tertiary-care 
teaching hospital in Seoul, South Korea. The study was conducted according to the Declaration of Helsinki, the 
protocol approved an exemption by the Institutional Review Board (IRB) of KUMC, and obtaining informed con-
sent from the study patients was not necessary (IRB approval No. KUH1200110). The data collection was done 
at the Department of Laboratory Medicine, Konkuk University Medical Center from February 2019 to March 
2019. The data was anonymized due to the sensitivity of patients’ information. CPD parameters and International 
Classification of Diseases, 10th Revision (ICD-10) codes were included. The demographic patient information, 
i.e., gender and age, were also included for better prediction outcomes.
We performed the hematologic analysis using Mindray BC-6800 (Mindray, Shenzhen, China) automated 
hematology analyzer that yielded CPD including CBC, leukocyte differentiation and reticulocyte count with 
information on volume, conductivity and different scatter measures23. After preprocessing (see the following 
section), a total of 882 cases were included for analysis. Detailed number of hematologic diseases including malig-
nancies and non-malignancies are shown below in Table 1.
Preprocessing. The dataset contained several missing values. We handled this issue in two steps. First, the 
cases that had more than 90% values missing were excluded. In total, 17 cases were excluded, while 882 cases were 
further analyzed. Second, missing values were predicted with two machine learning algorithms. The missing 
numerical variables were predicted with linear regression, while the missing categorical variables were predicted 
ICD-10 
Code Type Cases Group
C81-C96 Malignant neoplasms of lymphoid, haematopoietic and related tissue 457 Hematologic - Malignancies
D50-D53 Nutritional anemia 49 Hematologic – Non Malignancies
D55-D59 Haemolytic anemia 6 Hematologic – Non Malignancies
D60-D64 Aplastic and other anemia 166 Hematologic – Non Malignancies
D65-D69 Coagulation defects, purpura and other hemorrhagic conditions 83 Hematologic – Non Malignancies
D70-D77 Other diseases of blood and blood-forming organs 121 Hematologic – Non Malignancies
Table 1. Case numbers analyzed in the study (after preprocessing).
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with decision tree classifier. In both cases, the learning data contained a subset of numerical attributes and a sub-
set of instances with no missing values.
After handling missing values, we selected only laboratory data and demographic patient information (gender 
and age) for further analysis. As a result, the number of variables (before feature selection) was 61.
There are different ranges of measurements and units in the laboratory data, therefore, in order to normalize 
our dataset, we used the scaling process. We selected Min-Max Scalar as scaling feature to transform the normal 
values to end up within the range of 0 to 1. In order to make the gender values in numerical form, we used the 
value of 0 for female and 1 for male.
Bias variable. We applied point-biserial correlation to determine which variables have significant influence 
on malignant or non-malignant hematologic diseases. Point-biserial correlation is assessed between −1 to 1. The 
value closer to −1 shows the strong confidence of negative linear relationship between two variables, and the 
value closer to 1 shows strong confidence of positive linear relationship.
The presented approach uses filter-based variable/feature selection. However, there exist two additional 
approaches for selecting the most appropriate features: wrapper and embedded approaches. The main differences 
among them are the following. Filter methods use a selected measure to get the best subset of features prior 
machine learning phase. Wrapper methods use machine learning model to score the feature subsets and select 
the best performing one. Embedded methods perform feature selection as a part of model construction process.
Variable selection. In order to find out the variables with high significance, either negative or positive 
point-biserial correlation, we used the absolute value by changing the results from negative correlation to positive 
value, and ranked them from high to low. Table 2 shows the selected variables based on point-biserial correlation.
Model selection. In our study, we applied seven machine learning models: Stochastic Gradient Descent 
(SGD), Support Vector Machine (SVM), Random Forests (RF), Decision Tree (DT), an adapted Linear Regression 
– its output was discretized into two classes by using a threshold – (LINEAR), Logistic Regression (LOGIT), and 
Artificial Neural Networks (ANN). The first six models were used from the Scikit-learn library24 with the default 
parameter values, while ANN used the Keras library25.
ANN consisted of a 3-layer architecture and was trained in 300 epochs with batch size 48. The first hidden 
layer had 128 nodes with Rectified Linear Unit (ReLU) activation function, and the second hidden layer had 
64 nodes with ReLU activation function. A single node with Sigmoid/Logistic activation was used for the out-
put layer. The output layer was defined as malignancies predictive value, which is a continuous variable from 0 
(haematologic non-malignancies) to 1 (haematologic malignancies). This architecture was selected based on our 
past experience on processing similar medical datasets. A more appropriate approach for the selection of the 
architecture would include evaluation of various parameter values (such as number of layers). However, such an 
optimization is very complex and time-consuming thus will be carried out in future work if deemed necessary.
Performance evaluation. To evaluate the performance of the ML models, we used the stratified 10-fold 
cross-validation. In stratified cross-validation, the folds are selected in such a way that the percentage of sam-
ples is preserved for each class26. That is, the procedure maintains the same distribution of the target variable 
when randomly selecting examples for each fold; in our case, the same proportion between malignant and 
non-malignant cases. More precisely, this procedure divides the set of cases into k groups (k = 10) or folds of 
approximately equal sizes. The first fold is treated as a testing set, and the remaining k-1 folds are used for training 
the model (90% training data vs. 10% testing data). This is repeated 10 times, each time selecting a different fold 
as the testing set and the remaining folds as the training set. The performance metrics are then averaged over all 
the 10 steps. To avoid double dipping, training and testing sets (folds) are always disjoint sets and thus they do 
not share any sample27.
In our study we tested data with True Positive (TP) as real malignancies that are correctly predicted, False 
Positive (FP) as real malignancies that are incorrectly classified to be non-malignancies, True Negative (TN) 
as real non-malignancies that are correctly predicted, and False Negative (FN) as real non-malignancies that 
are incorrectly predicted. The results of tested performance measures from precision denotes the proportion of 
predicted positive cases or TP. Recall refers to sensitivity, and in medical term to identify all positive cases or rate 
of TP. Accuracy is predicting the correct ratio of samples, and is one of the most intuitive and basic performance 
measures for any ML model. Area Under the Curve (AUC) is used to determine the best cutoff point and compare 
two or more tests or observers of each calculated fold28. AUC compares rate of TP (TPR) and rate of FP (FPR). It 
is created by plotting the TPR against the FPR29.
Results
Comparative analysis of gender on malignant and non-malignant group revealed different results. We found that 
males in our set have a higher ratio in malignancies with 277 cases, as opposed to females with 180 cases. Among 
non-malignant groups that had opposite results, females had higher ratio with 266 cases than males with 159 
cases. The demographic population distribution on malignant and non-malignant group is shown in Table 3.
The classification information from our dataset was placed into two groups, haematologic malignancies and 
haematologic non-malignancies using ICD-10 code. As shown in Table 4, C92 or myeloid leukemia disease had 
the highest percentage (20.07) in malignant group with 177 cases, in which 167 cases belonged to acute myeloid 
leukemia disease. In Non-Malignant group, D64 Pancytopenia took the highest cases with a total of 106 followed 
by D61 with 60 cases.
The performance of the ML models was measured with 10-fold cross-validation as described in Section 
Performance Evaluation. In addition to the ML models, we also evaluated variable selection with thresholds 0.05, 
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0.1, 0.15, and 0.2 (see Table 5). When evaluating a threshold, all the variables with lower absolute point-biserial 
correlation were removed from the dataset. The results show that, for all the tested thresholds, the highest AUC is 
obtained by ANN. In addition, since there is low difference in AUC when applying the threshold of 0.05 in com-
parison to when no threshold is applied, the recall was also evaluated and the results show that recall is the highest 
Abbreviation Name
Absolute 
Correlation
P-LCC Platelet-large cell count 0.351
PCT Plateletcrit 0.336
PLT optical impedance 0.321
PLT-I Platelet count- Impedance 0.320
InR‰ Infected RBC percentage 0.297
Age Age 0.282
Gender Gender 0.231
HFC% High fluorescent Cell percentage 0.223
Neu-BF% Neutrophils percentage -body fluid 0.210
H-NR% High forward scatter NRBC ratio 0.198
PLR Platelet-to-lymphocyte ratio 0.188
Neu-BF# Neutrophils Number -body fluid 0.186
HF-BF# High Fluorescent cell Number -body fluid 0.181
NLR Neutrophil-to-lymphocyte ratio 0.181
L-NR% Low forward scatter NRBC ratio 0.179
Mon% Monocytes percentage 0.168
MO-BF% Monocytes percentage- body fluid 0.166
LY-BF% Lymphocytes percentage- body fluid 0.157
Eos-BF# Eosinophils number -body fluid 0.152
RDW-CV Red Blood Cell Distribution Width Coefficient of Variation 0.149
IMG% Immature Granulocyte percentage 0.146
Micro# RBC microcyte Cell Number 0.143
Micro% RBC microcyte Cell percentage 0.142
RDW-SD Red Blood Cell Distribution Width Standard Deviation 0.141
Macro# RBC macrocyte Cell Number 0.130
HCT Hematocrit 0.128
IME% Immature eosinophil percentage 0.114
HGB Hemoglobin Concentration 0.110
MCHC Mean Corpuscular Hemoglobin Concentration 0.100
RBC Red Blood Cell count 0.098
Macro% RBC macrocyte Cell percentage 0.096
Lym# Lymphocytes number 0.095
MPV Mean Platelet Volume 0.093
MCV Mean Corpuscular volume 0.091
LY-BF# Lymphocytes number- body fluid 0.090
Bas% Basophils percentage 0.089
MO-BF# Monocytes number- body fluid 0.084
P-LCR Platelet-large cell ratio 0.075
Eos-BF% Eosinophils percentage -body fluid 0.064
NRBC# Nucleated red blood cell number 0.059
NRBC% Nucleated red blood cell percentage 0.057
Table 2. CPD selected variables based on point-biserial correlation.
Age
Malignancies Non-Malignancies
Total (%)Female (%) Male (%) Female (%) Male (%)
<18 (Children) 0 (0) 3 (0.34) 1 (0.11) 1 (0.11) 5 (0.57)
18–64 (Adults) 124 (14.06) 207 (23.47) 152 (17.23) 63 (7.14) 546 (61.90)
65 + (Elderly) 56 (6.35) 67 (7.60) 113 (12.81) 95 (10.77) 331 (37.53)
Total 180 (20.41) 277 (31.41) 266 (30.16) 159 (18.03) 882 (100)
Table 3. Demographic population distribution.
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when the threshold of 0.05 is applied. Consequently, we selected variable selection with the threshold of 0.05 for 
further analysis. Such a variable selection eliminated 20 variables, as shown in Table 5.
The results of all the ML models when applying variable selection with the threshold of 0.05 are shown in 
Fig. 1 and Table 6. These figure and table show that ANN has the best performance among ML algorithms. More 
precisely, the diagnostic ability of ANN achieved the highest accuracy, precision, recall (diagnostic sensitivity) 
and AUC ± Standard Deviation as follows: 82.8%, 82.8%, 84.9%, and 93.5% ± 2.6 respectively.
For the statistical comparison of the algorithms, we applied Dietterich’s 5×2-Fold Cross-Validation method30. 
This method performs K-fold paired t test in order to compare the performance of two algorithms. The statistical 
comparison of the algorithms is shown in Table 7. This table shows that, assuming the level of significance of 0.05, 
the performance of ANN is significantly different with respect to the performance of other models.
Discussion
An ample amount of research has been done by utilizing AI and patients’ clinical information for diagnosis and 
management of various diseases. Here, our comparative analysis will focus on AI based studies in the literature 
that have utilized CBC and particularly CPD for screening hematologic malignancies. The morphological identi-
fication of blood cell disorders with CPD is critical for the early diagnosis and clinical decision. Accordingly, CPD 
could be used to assist physicians who are not specialized in haematology by facilitating the CBC and suggesting 
proper and early patient referral. In a study using CBC test data, three data mining methods: association rules, 
rule induction and deep learning were tested and the results showed that the deep learning classifier with the best 
ability for predicting tumors from blood diseases with an accuracy of 79.45%, with the limitation of no explana-
tion of results31. Another related study32 used machine learning algorithm to differentiate lymphoid classification 
using CPD parameters from 3 cohorts: healthy control, viral infection and chronic lymphocytic leukemia. In that 
study, the best result came from Neural Networks classifier with an accuracy of 98.7% followed by SVM 98.0% 
and KNN 98.0%32. A recent study using CPD showed Random Forest algorithm as the best model with two 
Group ICD code Disease category Frequency Percentage (%)
Malignant Group
C81 Hodgkin lymphoma 9 1.02%
C82 Follicular lymphoma 1 0.11%
C83 Non-follicular lymphoma 50 5.67%
C84 Mature T/NK-cell lymphomas 10 1.13%
C85 Other specified and unspecified types of non-Hodgkin lymphoma 28 3.17%
C86 Other specified types of T/NK-cell lymphoma 22 2.49%
C88 Malignant immunoproliferative diseases and certain other B-cell lymphomas 15 1.70%
C90 Multiple myeloma and malignant plasma cell neoplasms 20 2.27%
C91 Lymphoid leukemia 73 8.28%
C92 Myeloid leukemia 177 20.07%
C94 Other leukemias of specified cell type 13 1.47%
C95 Leukemia of unspecified cell type 38 4.31%
C96 Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue 1 0.11%
Non-Malignant Group
D50-D53 Nutritional anaemias 49 5.56%
D55-D59 Haemolytic anaemias 6 0.68%
D60-D64 Aplastic and other anaemias 166 18.82%
D65-D69 Coagulation defects, purpura and other haemorrhagic conditions 83 9.41%
D70-D77 Other diseases of blood and blood-forming organs 121 13.72%
Malignant Group C81-C96 457 51.81%
Non-Malignant Group D50-D77 425 48.19%
Total 882 100%
Table 4. Granularity information of group diseases in dataset.
Used variable
Total Variable 
Predictor Model
AUC % (± Standard 
Deviation) Recall
All Variables 61 ANN 93.9 ± 3 84.2
>0.05 41 ANN 93.5 ± 3 84.9
>0.1 29 ANN 92.8 ± 3 83.6
>0.15 19 ANN 90.7 ± 5 82.8
>0.20 9 ANN 87.7 ± 5 79.1
Table 5. Total variable predictor on selection variable and model with high result AUC and recall.
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practices, using all parameters and reduced parameters. It showed the accuracy of 59% for 181 parameters and 
accuracy of 57% for 61 parameters22. Another study took CPD data with 103 parameters for prediction of relapse 
in childhood with Acute Lymphoblastic Leukemia33. It showed the Random Forest as the best model for predic-
tion with measurements (accuracy: 83.1%; specificity 89.5%; positive predictive value: 88.0% and AUC: 90.2%). 
One slightly different retrospective study34 in the field of medical imaging with 467 cases (training set: 360 and 
test set: 107) constructed SVM texture classifier model to see the feasibility of differentiating bone marrow with 
hematologic diseases. With the above-mentioned training set, the values of accuracy, sensitivity and specificity 
and AUC were 82.8%, 81.7%, 83.9% and 0.895 (p < 0.001) respectively. The model’s predictive performance was 
comparable to the radiologists, but it requires more clinical and lab work for the finalization.
In our study, the results showed that machine learning approach, using deep learning algorithm trained on 
large amount of multi-analyte sets from laboratory blood test results, is able to predict diseases with high accu-
racy. Under these conditions, a classification (diagnostic) accuracy of 82.8% (ANN) and AUC 93.5% for the two 
classifications represent excellent results; and ANN are comparable to that of other ML methods have significance 
improvement.
Moreover, our results showed that the step of filtering variables based on point-biserial correlation had better 
results. Total variable predictor without filtered by point-biserial correlation would contain weak association with 
the classes. This suggests that there is a bias to assess malignancies and non-malignancies classes for choosing 
variables on CPD. Therefore, the highest selection that eliminated predictor with point-biserial correlation below 
2 is not covered as outstanding result because AUC performance decreased from 93.9 to 87.7% (see Table 5). 
Figure 1. AUC Obtained with ML Models when Applying Variable Selection with the Threshold of 0.05.
AUC ± Standard 
Deviation Accuracy Precision Recall
Stochastic Gradient Descent (SGD) 0.823 ± 0.040 0.699 0.746 0.710
Support Vector Machine (SVM) 0.792 ± 0.035 0.716 0.719 0.744
Decision Tree (DT) 0.782 ± 0.039 0.728 0.745 0.722
Ramdom Forest (RF) 0.859 ± 0.027 0.778 0.803 0.764
Linear Regression (LINEAR), adapted 0.802 ± 0.019 0.721 0.726 0.742
Logistic Regression (LOGIT) 0.822 ± 0.034 0.725 0.741 0.724
Artificial Neural Network (ANN) 0.935 ± 0.026 0.828 0.828 0.849
Table 6. Model performance indicators when applying variable selection with the threshold of 0.05.
SVM DT RF LINEAR LOGIT ANN
SGD 0.329 0.497 0.238 0.577 0.773 0.019
SVM 0.187 0.051 0.123 0.165 0.010
DT 0.161 0.304 0.892 0.002
RF 0.099 0.104 0.000
LINEAR 0.507 0.010
LOGIT 0.005
Table 7. The p values of testing hypothesis that pairs of algorithms perform similarly.
7Scientific RepoRtS |         (2020) 10:4583  | https://doi.org/10.1038/s41598-020-61247-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
This type of predictor has an excellent selection but it has to be filtered to eliminate the weak association of the 
variable. Our results encourage further work of applying machine learning to the wider field of internal medicine.
As far as the association of platelet-large cell count with malignancy is concerned, a high blood platelet count 
is a strong predictor of cancer and should be urgently investigated further. A high platelet count may be referred 
to as thrombocytosis. This is usually the result of an existing condition (also called secondary or reactive throm-
bocytosis), such as: cancer - most commonly lung, gastrointestinal, ovarian, breast or lymphoma. Also, optimal 
impedance (PLT) is an advanced technique that provides an accurate automated complete blood count (CBC), 
including white blood cell (WBC) differential, in a short turnaround time. Clinically, it makes sense that PLT is 
among top influential variables in the model.
There were certain limitations in our study. It used a relatively small sample size and many cases were excluded 
for the main purpose of the study. The data collection process took two months, and we excluded data due to the 
machine learning algorithm restriction of high missing items. Due to the sample size, we focused on CPD and 
used the stratified cross-validation method. Moreover, we did not perform validation with external data, as we 
worked with the accumulated dataset only. Hence, the diagnostic ability of machine learning using other external 
data, e.g. (gene expression data) should be applied in the future. Our study mainly focused on predictive accuracy 
and did not look at the other additional benefits from CPD. For future investigations, we suggest the following 
potential areas for further investigation: predictive performance, counting identifying tasks and metrics, testing 
different approaches for data modeling, and understanding portions of the data have contrasting contributions 
to predictive accuracy. Furthermore, since genomic analysis is already a part of the clinical practice for the diag-
nosis and management of diverse hematologic malignancies, so the genomic evaluation of cancer supported by 
upcoming improvements in molecular diagnostic technologies is another key area that must be considered for 
the future research.
Conclusions
This research presents a novel approach of using ML algorithm for screening patients with suspected hematologic 
malignancies versus non-malignancies using CPD that was generated by routine CBC. We observed outstanding 
performance results on ANN model, as the diagnostic ability of ANN achieved higher accuracy, prediction, recall 
and AUC as compared to the other ML models. Therefore, we conclude that based on CPD, the ANN algorithm 
appears to be an efficient aid for the clinical laboratory diagnostic approach of hematologic malignancies. In the 
future, we are planning to apply this algorithm to the outpatient data in hematology departments. Prospective 
research and trials are mandatory to confirm the validity of clinical AI before it actually helps physicians in clini-
cal practice, particularly in haematologic diseases.
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